Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation
NCT01378026 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2011-06-22
Summary
G72 gene is located on the common linkage locus in bipolar disorder and schizophrenia, and it encodes D-amino acid oxidase activator (DAOA). There are evidences that elucidated G72 and D-amino acid oxidase(DAO) together playing a critical role in the pathophysiology of schizophrenia. Recently, reports discovered missense mutations in the DAO (R199W DAO and R38H DAO) are associated with familial amyotrophic lateral sclerosis (FALS), and our preliminary data showed that the level of G72 autoantibody decreases in patients with ALS compared with normal control. Thus, we want to find out whether G72 plays a role in ALS and neurodegenerative diseases including Alzheimer disease and Parkinson's disease. First, we detect G72 protein and its autoantibody in sera of neurodegenerative diseases patients using ELISA and Western blotting, and the data are compared with normal control. We hypothesize the levels of G72 protein and its autoantibody in neurodegenerative diseases are less than those in normal control. Then, we extract genomic DNA of neurodegenerative diseases patients, and use polymerase chain reaction(PCR) to detect single nucleotide polymorphism (SNP) of G72. We aim to detect G72 missense SNP variants presented in ALS, AD and PD.
Conditions
- Amyotrophic Lateral Sclerosis
- Alzheimer Disease
- Parkinson's Disease
Sponsors & Collaborators
-
China Medical University Hospital
lead OTHER
Eligibility
- Min Age
- 32 Years
- Max Age
- 87 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-01-31
More Related Trials
-
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
NCT03790085 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
NCT03784222 ·Status: TERMINATED ·Phase: PHASE4
-
Prediction of Violent Behavior in Patients With Schizophrenia by Multimodal Machine Learning
NCT04520399 ·Status: UNKNOWN
-
The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia
NCT00247637 ·Status: COMPLETED
-
The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome
NCT02093858 ·Status: UNKNOWN
-
A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
NCT01075373 ·Status: UNKNOWN
-
The Gut Metagenome Research of Schizophrenia
NCT02708316 ·Status: UNKNOWN
-
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
NCT01503359 ·Status: COMPLETED ·Phase: PHASE2
-
Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia
NCT07139171 ·Status: RECRUITING
-
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
NCT07230652 ·Status: RECRUITING ·Phase: PHASE1
-
Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia
NCT01295411 ·Status: UNKNOWN ·Phase: NA
-
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
NCT00960219 ·Status: COMPLETED ·Phase: PHASE2
-
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
NCT00207064 ·Status: COMPLETED ·Phase: NA
-
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
NCT06270108 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Emotion Endophenotypes in Schizophrenia
NCT02834208 ·Status: UNKNOWN ·Phase: NA
-
Biomarker Study of Acamprosate in Schizophrenia
NCT00688324 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia
NCT06700967 ·Status: NOT_YET_RECRUITING
-
The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism
NCT02552758 ·Status: UNKNOWN ·Phase: NA
-
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
NCT04822883 ·Status: COMPLETED ·Phase: PHASE2
-
tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.
NCT07074704 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Epigenetic Regulation of BDNF in Schizophrenia
NCT01021449 ·Status: COMPLETED
-
Validation of a Clinical Screening Grid for Syndromic Schizophrenia
NCT02746510 ·Status: TERMINATED ·Phase: NA
-
Cognitive Remediation Therapy in Schizophrenia: Effects on Epigenetics
NCT04278027 ·Status: UNKNOWN ·Phase: NA
-
The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients
NCT03007303 ·Status: UNKNOWN
-
Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
NCT02868879 ·Status: COMPLETED